Plasma and urine glucose concentrations were measured using a hexokinase enzymatic assay, and plasma insulin concentration was determined using an electrochemiluminescent sandwich immunoassay (Roche Diagnostics, Indianapolis, IN).
After the sample was centrifuged at 14,000 × g for 10 min at RT, the supernatant was used for glucose analysis using a hexokinase-dependent assay kit (Sigma, Inc., Cat. G3293) according to the manufacturer's instructions.
Fasting blood glucose was analyzed using a hexokinase method (GLU Flex of Dade Behring, Germany), fasting triglycerides (TG) with the TGL Flex GPO-PAP assay of Dade Behring and the analysis of total cholesterol wase carried out using the analyzer Dimension RxL (Dade Behring, Germany).
Fasting glucose was measured using a hexokinase method.
FPG measurements were performed using a hexokinase enzymatic method (19).
Briefly, FPG was measured using a hexokinase enzymatic method, with a coefficient of variation of 1.3 2.2%.
Glucose was measured by an automated Technicon Axon analyzer (Bayer Diagnostics, Sydney, Australia) using a hexokinase method.
Serum glucose was measured using a hexokinase enzymatic method (Roche Diagnostics, Indianapolis, IN, USA).
Glucose was determined using a hexokinase method (Roche Modular Analyser; Roche, Indianapolis, IN, USA).
Plasma glucose was measured using a hexokinase method (Olympus America, Melville, NY).
